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Background: The debate regarding ‘When to Start’ antiretroviral therapy has raged since the introduction of
zidovudine in 1987. Based on the entry criteria for the original Burroughs Wellcome 002 study, the field has been
anchored to CD4 cell counts as the prime metric to indicate treatment initiation for asymptomatic individuals
infected with Human Immunodeficiency Virus. The pendulum has swung back and forth based mostly on the
relative efficacy, toxicity and convenience of available regimens.
Discussion: In today’s world, several factors have converged that compel us to initiate therapy as soon as possible:
1) The biology of viral replication (1 to 10 billion viruses per day) strongly suggests that we should be starting early.
2) Resultant inflammation from unchecked replication is associated with earlier onset of multiple co-morbid
conditions. 3) The medications available today are more efficacious and less toxic than years past. 4) Clinical trials
have demonstrated benefits for all but the highest CD4 strata (>500 cells/μl). 5) Some cohort studies have
demonstrated the clear benefit of antiretroviral therapy at any CD4 count and no cohort studies have
demonstrated that early therapy is more detrimental than late therapy at the population level. 6) In addition to the
demonstrated and inferred benefits to the individual patient, we now have evidence of a Public Health benefit
from earlier intervention: treatment is prevention.
Summary: From a practical, common sense perspective we are talking about life-long therapy. Whether we start at
a CD4 count of 732 cells/μl or 493 cells/μl, the patient will be on therapy for over 40 to 50 years. There does not
seem to be much benefit in waiting and there likely is significant long-term harm. Do not wait. Treat early.
The counter-argument to this debate topic can be freely accessed here: http://www.biomedcentral.com/1741-7015/11/148.
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“All Scientific work is incomplete - whether it be
observational or experimental. All scientific work is
liable to be upset or modified by advancing knowledge.
That does not confer upon us a freedom to ignore the
knowledge we already have, or to postpone the action
that it appears to demand at a given time.”
- Sir Austin Bradford Hill [1].
In 1986 zidovudine (AZT) had a striking efficacy in
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distribution, and reproduction in any mediumImmunodeficiency Virus (HIV) infection and advanced
Acquired Immunodeficiency Syndrome (AIDS). Those
patients had very low CD4 T cell counts, profound im-
munodeficiency and a very high risk of developing op-
portunistic infections (OIs), especially Pneumocystis
jirovecii pneumonia. After 24 weeks of treatment, 19 pla-
cebo recipients and 1 AZT recipient died (P <0.001).
This remarkable benefit of AZT led to early discontinu-
ation of the placebo-based, first successful HIV treatment
trial [2]. These compelling results soon made investiga-
tors interested in the potential benefits of treatment at
earlier stages of the disease, prior to the development of
OIs or drops in CD4 T cell counts to below 200 cells/μl
[3]. However, subsequent trials of AZT monotherapy in
patients with early infection failed to show evidence of
durable benefit in halting the progression of the disease
and longer survival [3-5]. The reverse transcriptasetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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sine, zalcitabine, and stavudine - also were relatively weak
antiretroviral agents that at best lowered the viral load by
0.7 log10 copies/ml and their individual use was followed
by breakthrough HIV viremia with resistant virus [6,7].
Over subsequent years substantial progress was made
in developing more potent antiretroviral agents and regi-
mens. Novel inhibitors of the HIV protease, such as rito-
navir and indinavir, were able to lower plasma viremia
by 2.0 log10 copies/ml and certain non-nucleoside
blockers of the reverse transcriptase, such as nevirapine,
exhibited inhibitory effect of 1.0 to 1.5 log10 copies/ml
[8,9]. Combination therapy, which came into vogue in
the early 1990s, of zidovudine plus lamivudine had
shown a promising activity of about 1.7 log10 copies/ml
in vivo [7]. The advent of highly active antiretroviral
therapy (HAART) by the mid-1990s brought new hopes
for the advocates of the “hit early, hit hard” approach
[10]. However, subsequent studies analyzing patient co-
horts on earlier HAART regimens would still show no
difference in HIV-related complications or mortality
comparing early initiation of HAART (CD4 T cell
counts ≥350 cells/μl) versus delayed HAART initiation
(CD4 cell counts of 200 to 350 cells/μl) [11,12]. The
cumulative toxicities and poor tolerability of initial
HAART regimens, the negative impact of pre-existent
HIV resistance among those treated with inadequate
regimens years before HAART, and the need for life-
long treatment made clinicians and guidelines eventu-
ally move away from this strategy [13,14].
The debate regarding optimal time to initiate antiretro-
viral (ARV) therapy has continued since the early years of
HAART [15,16] and remains active in the current stage of
therapies against HIV [17]. Herein, we enumerate several
reasons why HIV should be treated as early as possible in
today’s world. Arguments to the contrary are outlined in a
debate article published in BMC Medicine [18].
Discussion
The biology
During AZT monotherapy, an 80% reduction in viral
load (0.9 log10 copies/ml) was noted as soon as one week
after initiation of therapy followed by a fast, nearly sym-
metric return to baseline levels within one week after
treatment discontinuation [19]. Subsequent viral dynam-
ics studies using more potent HIV protease and reverse
transcriptase inhibitors showed how fast rounds of de
novo virus infection occur, making 1 to 10 billion new
viral copies per day [9,20]. With this magnitude of repli-
cation, it was estimated that both the viral life cycle and
the half-life of infected CD4 T cells were as short as one
day or less with several million CD4 T cells being
infected each day [20]. These findings had a deep impact
on the understanding of how destruction of the immunesystem occurs and why CD4 counts decline over time,
even during the period of “clinical latency” [9]. Based on
the above, it has been reasonable to consider that early
and profound suppression of the HIV replication brings
several benefits: it reduces the high levels of ongoing in-
flammation, creates a higher virologic hurdle for its
emergence and preserves the immune system integrity
before there is loss of vital clones of responsive cells
[21]. Indeed, the biology strongly suggests that inhibition
of relentless cycles of viral replication should be accom-
plished as soon as possible.
The association of inflammation and disease
The breakthroughs in understanding HIV pathogenesis
fueled subsequent research beyond the boundaries of
unchecked viral replication. Uninterrupted CD4 T cell
activation and apoptosis are the hallmarks of both HIV
disease progression as well as the basis of a persistent in-
flammatory state, which is associated with deleterious
cardiovascular and metabolic consequences to the host
[22]. Although the reduction of T cell activation (and in-
flammation) brought by effective therapy never reaches
‘normal’ levels (as measured in uninfected controls) [23],
early therapy substantially reduces residual T cell activa-
tion compared with that in subjects not on therapy [24].
Even though a cause-effect relationship is unproven at
this point, elevated inflammatory biomarkers, such as D-
dimer, C-reactive protein, hyaluronic acid, and soluble
CD14, all correlate with the risk for all-cause mortality
among infected subjects [25-29]. This association adds
further momentum to initiation of ARV therapy earlier
to minimize the duration of exposure to high levels of
inflammation [23].
Schouten and colleagues have recently shown that the
prevalence of non-AIDS comorbidities in HIV-infected
adults aged 50 to 55 years was comparable to uninfected
adults older than 65 years of age. This verified earlier
onset of comorbid conditions occurred despite having
84% of the HIV-infected patients with undetectable viral
loads and remained consistent even after controlling for
factors such as age, gender and smoking [30]. Despite in-
trinsic ascertainment bias in studies of this kind, these
findings highlight the potential role of exposure to in-
flammation on non-AIDS comorbidities, which are the
leading cause of death in HIV-infected patients today. It
also provides a “sense of urgency” in the initiation of
treatment. The mean CD4 count nadir in the study was
330 cells/μl and the mean CD4 count the year prior to
enrollment was 548 cells/μl. Considering that the mean
length of infection prior to treatment initiation was 11
years, it seems that this population received treatment
relatively early, but not nearly enough in order to have
outcomes comparable to uninfected controls. In the Vet-
erans Aging Cohort Study (VACS), Althoff and
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adjusted incidence of myocardial infarction (MI), end-
stage renal disease (ESRD) and AIDS-related cancers
(lung, liver, anal, oropharyngeal cancers and Hodgkins
lymphoma). Age of diagnosis did not differ between the
HIV-positive and HIV-negative groups, providing little
evidence for the concept of premature aging. Neverthe-
less, the much higher incidence of hard outcomes, such
as MI, ESRD and cancer, is complementary to the hy-
pothesis of earlier development of pre-morbid condi-
tions in HIV [31]. Moreover, in a study by van Sighem
and colleagues, a cohort of 13,077 people diagnosed with
HIV in 1998 or later was analyzed. In this treatment-
naïve population, those who initiated therapy with
CD4 counts below 200 more than quadrupled the risk
of the composite non-AIDS endpoints (major cardio-
vascular diseases, liver cirrhosis and non-AIDS malig-
nancies) than those who initiated treatment with CD4
counts >500 cells/μl. Counts between 200 and 349 cells/μl
were associated with a more than doubled risk, and risks
for those with counts between 350 and 499 cells/μl were
not significantly different from those with >500 cells/μl,
though there was a trend toward higher risk of the
composite endpoint (RR 1.23, CI 0.85 to 1.78) [32]. Taken
together, these data show that ongoing chronic inflamma-
tion is a potential driving force behind morbidity and
mortality, a finding that has been cited as one of the major
scientific insights of the past decade [33].
Better tolerated medications today
Newer medications and formulations have addressed
many of the limitations of earlier regimens in terms of
short and long-term antiretroviral toxicities. Therapies
against HIV have become easier to administer, less toxic
and more potent. Undoubtedly, concerns about tenofovir-
associated kidney dysfunction, bone demineralization and
potential increases in cardiovascular disease risk remain
[34-37]. Nevertheless, newer protease inhibitors have been
associated with far fewer adverse effects, such as
dyslipidemia, insulin resistance and gastrointestinal in-
tolerance [38,39]. Likewise, newer nucleoside reverse-
transcriptase inhibitors have virtually no associated
lipodystrophy or major mitochondrial dysfunction [40].
Novel HIV treatments are able now to offer more con-
venient dosing. Fixed-dose combination options adminis-
tered once daily have led to more uniformity in initial
antiretroviral therapy. In assessing prescribing practices in
our clinic, the most dramatic shift in drug selection in-
volved the incremental use of emtricitabine plus tenofovir
plus efavirenz, from 0% in 2003 to 85% in 2007. This
reflected better acceptance of a simpler regimen that can
be administered as a single, daily pill [41]. These dramatic
advances have tremendously impacted clinical practice
and compelled clinicians and investigators to revisit thequestion of the ideal time to initiate therapy, weighing the
relative risks and benefits.Cohort data
Clinical research has continued to evolve, extracting evi-
dence from contemporary clinical practice. Data from
the North America-AIDS Cohort Collaboration on Re-
search and Design (NA-ACCORD) clearly demonstrated
that the adjusted mortality rates were statistically higher
among the 6,935 patients who deferred therapy until their
CD4 counts fell to <500 cells/μl than in the 2,200 patients
who started therapy with CD4 counts >500 cells/μl (risk
ratio: 1.94, 95% CI: 1.37 to 2.79). However, the absolute
risk of death was low in both groups: 5.1% in the deferred
therapy and 2.9% in the early therapy group [42].
Although large and representative of the HIV-infected
patients in care in the United States, the study had limita-
tions intrinsic to its retrospective design, including the
relatively small number of deaths and the potential for un-
measured confounders that might have influenced out-
comes independent of treatment. Indeed, two other large
cohort studies, the Antiretroviral Therapy-Cohort Collab-
orative (ART-CC) and the Concerted Action on SeroCon-
version to AIDS and Death in Europe (CASCADE)
collaboration, did not identify a benefit of earlier initiation
of therapy in reducing AIDS progression or death [43,44].
These studies, however, shared the same “limitations” of
the NA-ACCORD study, with a fortunate low proportion
of treated patients progressing to AIDS or death during
follow-up. The ART-CC study also was limited by the
period of observation beginning with initiation of therapy.
Of note, no cohort study to date has demonstrated any
clear evidence of greater harm among those initiating
therapy with CD4 counts >500 cells/μl. To the contrary,
most have shown trends toward benefit but, owing to
smaller numbers of patients in the >500 cells/μl group
and the relative absence of mortality events, did not dem-
onstrate statistical benefit (with the notable exception of
the NA-ACCORD study that did show statistical benefit).
Due to these intrinsic limitations of cohort studies in
analyzing rare outcomes, investigators have tried differ-
ent methods and designs in evaluating the evidence be-
hind early treatment. A recent clinical trial (Setpoint
Study) randomly assigned patients, who were within six
months of HIV seroconversion, to receive either imme-
diate treatment for 36 weeks or deferred treatment
(when CD4 counts were <350 cells/μl). More than 57%
of the study participants had CD4 counts >500 cells/μl.
The deferred treatment group had a statistically higher
risk of meeting treatment initiation criteria (for example,
CD4 <350 cells/μl) resulting in earlier discontinuation of
the study. While this study was not a clinical endpoint
study, these results illustrated that the time from
Franco and Saag BMC Medicine 2013, 11:147 Page 4 of 8
http://www.biomedcentral.com/1741-7015/11/147diagnosis of early infection to the need for initiation of
therapy was shorter than anticipated [45].
Other data support earlier initiation of treatment.
Chronically infected patients delaying therapy until CD4
T cells ≤350 cells/μl have suboptimal CD4 T cell count re-
covery. After six years of ARV therapy, those who delayed
therapy reached a CD4 count plateau below 500 cells/μl,
which was significantly lower than patients starting ther-
apy earlier [46].
The benefits of early treatment go beyond hard im-
munologic parameters and translate into a higher likeli-
hood of overall treatment success. The implementation
of universal treatment of all HIV-infected persons in a
large, publicly-funded clinic in San Francisco in 2010 led
to a six-fold increase in the probability of viral suppres-
sion. In 534 patients entering the clinic with CD4
counts >500 cells/μl, the one-year incidence of viral
suppression increased from 14% to >52% after adopting
the approach [47]. These results are complimentary to
data from another large outpatient cohort showing that
major resistance mutations were 50% less likely in pa-
tients starting therapy with CD4 count >350 cells/μl
versus <200 cells/μl despite greater treatment exposure
[48]. These data run counter to the ‘wait until later’
proponents who predicted that resistance would be
more common among those who started therapy earl-
ier. It is not more common; it is less. Given the
concerning reality of the low proportions of treatment
success in real life settings such as above, and the com-
pared success proportions often greater than 80% inFigure 1 When to start HAART among asymptomatic HIV + patients a
States are derived from the IAS-USA Treatment Guidelines and the Departm
Therapy for Adults and Adolescents; European guidelines are derived from
Health Organization (WHO) Guidelines are from the WHO Antiretroviral The
from Dr. Marco Vitoria, MD of the World Health Organization and the Massclinical trials, early treatment must be accompanied by
excellent individual care in order to ensure the highest
therapy adherence.
As we start to adopt the “test and treat” approach, data
from the Johns Hopkins HIV clinic have demonstrated
that starting therapy earlier is a cost-effective strategy by
the generally accepted benchmark in the US [49].
Guidelines
Many of the observational cohort studies have supported
the earlier initiation of HAART, resulting in a renewed
confidence among many guideline committees to recom-
mend initiation of therapy for those with higher CD4
counts in resource rich countries (see Figure 1). Yet,
guidelines for starting therapy for those in resource-
limited settings typically recommend starting therapy
later in the course of infection [50]. Ideally, no difference
should exist between guideline recommendations for
when to start treatment solely based on resources. Ra-
ther, the biologic evidence of when to start is very likely
the same regardless of location. However, resources
often may dictate what is implementable or not in a
given location. “Guidelines” are simply guidelines, not
directives or imperatives. They represent the ideal and it
is up to the local Ministries to decide what is feasible in
each location at any moment in time.
Public health
In addition to potential gains in viral load suppression
for the individual, in terms of improved outcomes andccording to guidelines: 1998 to 2012. Criteria from the United
ent of Health and Human Services Guidelines for Antiretroviral
the European AIDS Clinical Society (EACS) Guidelines; and the World
rapy Guidelines for Adults and Adolescents. Adapted with permission
achusetts Medical Society/New England Journal of Medicine [50].
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tially reduces new HIV infections at the community level
and, therefore, is extremely important from the stand-
point of public health. The results of the HIV Prevention
Trials Network (HPTN 052) proved this benefit un-
equivocally. This was a multi-continental trial that en-
rolled 1,763 HIV-serodiscordant couples comparing
immediate treatment versus delayed therapy for the
HIV-infected partner [51]. At study entry, 98% of the
participants were in heterosexual, monogamous relation-
ships and were counseled on behavioral modification
and condom use. Twenty-eight linked HIV transmission
events were identified during the study period, but only
one event occurred in the early therapy arm (and this
transmission occurred early into treatment before viral
load was fully suppressed). This 96% reduction in trans-
mission associated with early ART was highly significant
(hazard ratio (HR) 0.04; 95% confidence interval (CI):
0.01 to 0.27, P < 0.001). These results conveyed the mes-
sage that early therapy is more effective in preventing
transmission of HIV than all other behavioral and bio-
medical prevention interventions studied to date, includ-
ing condom use, male circumcision, vaginal microbicides,
HIV vaccination and pre-exposure prophylaxis.
Other observational studies and modeling analyses
have provided similar conclusions as it relates to a de-
creased rate of HIV transmission in serodiscordant het-
erosexual couples following the introduction of ART
[52-57]. In the United States, 25% of the infected adults
are unaware of their status and are responsible for >55%
of new infections [58]. HIV treatment is prevention. Al-
though public health interests should not be a primary
reason for early treatment initiation, these data do pro-
vide further rationale for earlier initiation of treatment.
Clinical trial data
Despite the high-quality, cohort-derived evidence and
the balance in favor of early treatment, some investiga-
tors remain skeptical and reluctant to adopt this strategy
due to the lack of clinical trials of early versus delayed
therapy for those with CD4 cell counts >500 cells/μl.
The Strategic Timing of Anti-Retroviral Treatment
(START) trial has been in enrollment phase and is
expected to provide the first randomized trial evidence
of whether immediate initiation of treatment in patients
with CD4 cell counts greater than 500 cells/μl is super-
ior to delaying initiation of HAART until the CD4 cell
count falls below 350 cells/μl [59]. Although clinical tri-
als are touted as the study modality capable of providing
the strongest evidence in guiding clinical practice, they
are not necessarily the right modality to answer all clin-
ical questions. In the case of ‘when to start’, several con-
founders and limitations exist. First, the time to
development of complications of either viral infection ordrug toxicity in these subjects who have relatively early
HIV disease is quite long. Therefore, a three-year study
endpoint likely is too soon to answer the question. Ra-
ther, the impact of ongoing, unchecked viral replication
likely will not become evident until many years later.
Findings similar to those described in the van Sighem
study, as outlined above [32], likely will emerge during
the early results of the START study; that is, trends to-
ward supporting the higher CD4 count group that will
require several years of further follow-up.
Second, although clinical trials have the advantage of
randomization, there still are inherent limitations in
study eligibility criteria and study referral patterns that
can limit the generalizability of the findings. In particu-
lar, the patients referred to this study will be only those
deemed to have clinical equipoise regarding when to
start treatment. Those who the clinicians either do not
want to treat now (poor treatment candidates or those
who are not willing to start treatment) or who they do
want to treat now (patients who need immediate treat-
ment and cannot wait for routine study procedures, in-
cluding extra time for randomization) will not be
referred to the study. This could represent up to three
quarters of potentially eligible patients. So, in essence,
some of the same ‘channeling biases’ present in clinical
practice and, therefore, cohort studies, are at play among
those individuals referred (or not referred) to a clinical
trial. If the question was whether to ever treat HIV, a
clinical trial seems like a great approach to answer the
question. In the case of defining subtle differences
within a narrow window of time, the results do not seem
worth the efforts and/or the costs.
Common sense
The decision to start early treatment is an event that oc-
curs in a relatively small window of time in the life span
of a person with HIV infection. While some patients
have stable CD4 counts over time (for example, “Elite
Controllers”), the majority experience drops in CD4
counts of 40 to 80 cells/μl/year. As an example, over as
few as two years, and on average five years, CD4 cell
counts can drop from 500 cells/μl to 350 cells/μl. Five
extra years of therapy out of a total of 40 to 50 years on
treatment for those living a near-normal life span (for
example, treatment from age 25 years to 75 years) repre-
sents relatively minor differences in long-term exposure
to treatment. However, those five extra years of contin-
ued exposure to unchecked viral replication represent
potential substantial harm as demonstrated by the
known biology of the infection. Rather than the ‘feared’
unnecessary exposure to drugs for only a fraction of a
person’s lifetime, the likely harm comes from relentless
replication of HIV, inflammation, destruction of lymph-
oid tissue, likely increased cardiovascular events, higher
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decline.
Summary
In conclusion, the balance of available data strongly sup-
ports starting treatment in nearly all individuals regardless
of CD4 T cell counts. Early treatment recommendations
are based on our understanding of HIV biology, HIV
pathogenesis, the availability of better drugs, the evidence
from cohort studies, and the public health implications of
viral load suppression and decreased transmission. Excep-
tions might be among the very small population of indi-
viduals who are ‘elite controllers,’ defined as those who
have undetectable virus in the absence of antiretroviral
therapy. For everyone else, to wait on randomized clinical
trial data could well be doing harm. The time spent
waiting is time that the patients cannot get back and the
long-term damage associated with waiting could well be
irreversible.
Just prior to the quote referenced in the Background
section above, Sir Austin Bradford Hill had stated:
“In asking for very strong evidence I would, however,
repeat emphatically that this does not imply crossing
every ‘t’, and swords with every critic, before we act” [1].
Until proven otherwise, we should heed Sir Austin
Bradford Hill’s admonition and act upon the evidence
we have in hand, which overwhelmingly tells us to treat
early. What are we waiting for?
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